Abstract
On a new aminoglycosidic antibiotic, lividomycin (LVM), produced in Japan, several laboratory and clinical investigations were performed and the following results were obtained.
1. MIC values of LVM to strains of Pseudomonas aeruginosa were distributed from 12.5 to 50mcg/ml.That of majority of other gram-negative bacilli ranged from 3.1 to 25mcg/ml.
2. The mode of action of LVM was chiefly bactericidal.
3. Discs of various antibiotics were applied on two types of agar plates: one contained certain level of LVM and another without LVM, and each of 10 strains of Pseudomonas aeruginosa was streaked on the surface of both plates.From the change of inhibition size in diameter it was examined whether synergistic action exists between LVM and any of other antibiotics.As a result, great enlargement of zone size was found in 5 of 10 strains tested in the case of gentamicin.
4. The comparison of therapeutic effect of daily intramuscular injections of LVM and carbenicillin after Pseudomonas subcutaneous infection to mice showed that LVM was superior to carbenicillin in the same dose treatment.
5. Horse serum protein binding rate using cellophane bag dialysis was low.
6. Adsorption to sheep red blood cells was also low.
7. Serum level after intramuscular injection of LVM to rabbits reached a peak level of more than100mcg/ml.
8. Bile level after intramuscular injection of LVM proved to be about one-third of serum level, but urine level was more than 10 folds of serum in the peak value.
9. Organ level following intramuscular injection to mice ranked in order of kidney, serum and lung, being undetectable in other organs.
10. By mixing LVM with each organ homogenate of mice, marked reduction of activity of LVM was observed.
11. In one clinical case, the level of collected urine during 24 hours was determined and excretion rate was calctlated.Good excretion into urine was noticed.
